Tuberculosis (TB) remains a significant public health concern in the 21st century, especially
due to drug resistance, coinfection with diseases like immunodeficiency syndrome (AIDS) …

Tuberculosis (TB) continues to be one of the deadliest infectious diseases in the world,
causing~ 1.5 million deaths every year. The World Health Organization initiated an End TB …

Purpose New strategies for developing inhibitors of Mycobacterium tuberculosis (Mtb) are
required in order to identify the next generation of tuberculosis (TB) drugs. Our approach …

Tuberculosis (TB) has become a global health threat in the wake of the Human
Immunodeficiency Virus (HIV) pandemic and is the leading cause of death in people with …

The current drug regimens for treating tuberculosis are lengthy and onerous, and hence
complicated by poor adherence leading to drug resistance and disease relapse. Previously …

In this chapter, we provide a comprehensive review of the recent developments and
challenges associated with tuberculosis drug discovery. The chapter begins with an …

Transcriptional profiling has revealed that Mycobacterium tuberculosis adapts both its
metabolic and respiratory states during infection, utilising lipids as a carbon source and …

To address the ongoing global tuberculosis crisis, there is a need for shorter, more effective
treatments. A major reason why tuberculosis requires prolonged treatment is that, following …

Development of new drugs to treat tuberculosis (TB) faces even more constraints than the
development of therapeutic agents for other diseases. This is due, in part, to intrinsic …

Progress toward developing new strategies to control the spread of Mycobacterium
tuberculosis is limited by a poor understanding of the basic pathogenesis of post‐primary …